3Spine Funding: How Much Did They Raise & Key Investors

How Much Did 3Spine Raise?
Funding & Key Investors

3Spine has successfully secured a significant capital injection, bringing its cumulative financing to $51.8M. This latest major strategic investment of $33M underscores the market confidence in the company's proprietary lumbar motion-enabling technology. By consolidating its financial position, the firm is well-positioned to accelerate its clinical research and operational footprint in the orthopedic medical device sector.

The company's growth trajectory, marked by successive rounds of investment, reflects a disciplined approach to scaling complex medical hardware. From its initial seed backing to this recent enterprise-level financing, 3Spine has demonstrated a consistent ability to attract the resources necessary to advance its revolutionary MOTUS platform through rigorous clinical validation.

What is 3Spine?

3Spine

Manufacturing

Medical Devices & Equipment

Business Services

3Spine operates as a vertically integrated healthcare entity dedicated to the development, clinical research, and delivery of total joint replacement solutions for the lumbar spine. Headquartered in Chattanooga, Tennessee, with specialized R&D facilities in the Greater Boston area, the company represents a paradigm shift in spinal care. Its flagship technology, MOTUS, is designed to restore natural balance and maintain range of motion, addressing a critical gap in traditional spinal fusion procedures. By controlling the entire value chain—from design to clinical delivery—3Spine aims to standardize outcomes and improve patient quality of life through biomechanical innovation.

How much funding has 3Spine raised?

3Spine has raised a total of $51.8M across 4 funding rounds:

2016

Angel/Seed

$1.5M

2018

Series A

$7.3M

2020

Series B

$10M

2022

Series C

$33M

Angel/Seed (2016): $1.5M, investors not publicly disclosed

Series A (2018): $7.3M, investors not publicly disclosed

Series B (2020): $10M, investors not publicly disclosed

Series C (2022): $33M featuring Byron DeFoor

Key Investors in 3Spine

Byron DeFoor

A private investor and strategic backer who has supported the company's growth through significant capital contributions.

Undisclosed Investor

Undisclosed investor participating in the funding round.

Undisclosed Investor

Undisclosed investor participating in the funding round.

What's next for 3Spine?

With the infusion of $33M, 3Spine is poised to transition from its intensive research phase into broader clinical implementation. The strategic roadmap likely involves expanding its clinical operations in the Cayman Islands and scaling its R&D capabilities to support the commercialization of the MOTUS system. As the company moves toward wider adoption, the focus will shift to long-term clinical data collection and regulatory milestones, ensuring that its motion-enabling technology becomes a standard of care for lumbar indications. The firm's ability to maintain its vertical integration model will be a key determinant in its long-term competitive advantage within the global orthopedic market.

See full 3Spine company page

See More Financial Insights